• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

    5/14/25 12:24:45 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 9)


    AKERO THERAPEUTICS, INC.

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    00973Y108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00973Y108


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,068,994.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,068,994.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,068,994.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AKERO THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    601 GATEWAY BOULDEVARD, SUITE 350 SOUTH SAN FRANCISCO, CA 94080
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    00973Y108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 7,004,324 shares
    (b)Percent of class:

    8.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    7004324

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    7004324

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $AKRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKRO

    DatePrice TargetRatingAnalyst
    1/30/2025$35.00 → $63.00Neutral → Buy
    BofA Securities
    1/27/2025$50.00 → $72.00Buy
    H.C. Wainwright
    11/18/2024$65.00Buy
    Citigroup
    4/22/2024$30.00Neutral
    BofA Securities
    9/19/2023$69.00Overweight
    Cantor Fitzgerald
    8/28/2023$83.00Buy
    UBS
    1/27/2023$40.00 → $65.00Equal-Weight → Overweight
    Morgan Stanley
    9/14/2022$10.00 → $50.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AKRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 3:59:41 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 1:22:38 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

      SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      11/14/24 6:51:23 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Commercial Strategy Lamy Patrick exercised 4,000 shares at a strike of $44.37 and sold $200,000 worth of shares (4,000 units at $50.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/23/25 5:30:04 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $21.10 and sold $392,978 worth of shares (10,000 units at $39.30) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/19/25 7:06:47 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Cheng Andrew sold $1,244,455 worth of shares (30,000 units at $41.48), decreasing direct ownership by 5% to 594,324 units (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      5/13/25 9:11:49 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a clinical-stage company develo

      5/28/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025 SYMMETRY study results published in New England Journal of Medicine Raised $402.5 million in gross proceeds in a follow-on public offering in January 2025, resulting in reserves of cash, cash equivalents, and marketable securities of $1,128 million at March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Ak

      5/12/25 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

      Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced results from new analyses of the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) in patients with pre-cirrhotic (F2-F3 fibrosis) metabolic dysfunction-associated steatohepatitis (MASH

      5/10/25 10:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      3/27/25 7:42:13 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      2/7/25 7:54:28 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graham G. Walmsley bought $1,982,940 worth of shares (100,000 units at $19.83) (SEC Form 4)

      4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

      12/11/23 9:06:30 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Financials

    Live finance-specific insights

    See more
    • Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

      Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15% By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12% Investor webcast at 8:00 am ET Monday, January 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious me

      1/27/25 6:30:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

      Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, January 27, 2025, at 8:00 a.m. ET to share preliminary topline week 96 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). Conferenc

      1/24/25 4:05:00 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

            50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) --  Akero Therapeutics,

      3/4/24 6:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/15/25 8:13:34 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Akero Therapeutics Inc.

      SCHEDULE 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/14/25 12:24:45 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Akero Therapeutics Inc.

      144 - Akero Therapeutics, Inc. (0001744659) (Subject)

      5/12/25 6:47:52 PM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AKRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Akero Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Akero Therapeutics from Neutral to Buy and set a new price target of $63.00 from $35.00 previously

      1/30/25 7:09:02 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Akero Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00 from $50.00 previously

      1/27/25 11:47:01 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Akero Therapeutics with a new price target

      Citigroup initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $65.00

      11/18/24 7:26:08 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second

      8/9/24 7:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

      SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to

      4/30/24 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

      SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra

      1/10/23 8:00:00 AM ET
      $AKRO
      Biotechnology: Pharmaceutical Preparations
      Health Care